Clearance of 25-hydroxyvitamin D in Chronic Kidney Disease



Status:Recruiting
Conditions:Renal Impairment / Chronic Kidney Disease
Therapuetic Areas:Nephrology / Urology
Healthy:No
Age Range:18 - Any
Updated:10/13/2018
Start Date:March 1, 2017
End Date:December 2020
Contact:Laura Curtin
Email:LCurtin@Nephrology.washington.edu
Phone:2062213938

Use our guide to learn which trials are right for you!

The goal of this study is to better understand vitamin D catabolism and how it is affected by
CKD and race. Specifically, the study team will evaluate the metabolic clearance of
25-hydroxyvitamin D3 in individuals with varying degrees of CKD and among participants who
self-report race as Caucasian, African American or African. The long-term goal of this work
is to enhance the clinical evaluation and treatment of impaired vitamin D metabolism.


Inclusion Criteria:

- Age ≥ 18 years

- Self-reported race Caucasian, African American, or African

- Serum total 25(OH)D 10-50 ng/mL

- Estimated GFR:

- 60 mL/min/1.73m2 (N=40) 15-45 mL/min/1.73m2 (N=40) <15 mL/min/1.73m2, treated
with hemodialysis (N=40)

Exclusion Criteria:

- Primary hyperparathyroidism

- Gastric bypass

- Tuberculosis or sarcoidosis

- Current pregnancy

- Child-Pugh Class B or C cirrhosis (i.e. cirrhosis with ascites, hepatic
encephalopathy, bilirubin >=2 mg/dL, serum albumin <=3.5 g/dL, or PT >= 4 seconds)

- Use of vitamin D3, or vitamin D2 supplements exceeding a mean daily dose of 400 IU,
within 3 months (wash-out allowed)

- Use of 1,25(OH)2D3 or an analogue, calcimimetics, or medications known to induce
CYP24A1 within 4 weeks (wash-out allowed)

- Serum calcium > 10.1 mg/dL

- Hemoglobin < 10 g/dL
We found this trial at
1
site
Seattle, Washington 98104
(206) 543-2100
Phone: 206-221-3938
Univ of Washington Founded in 1861 by a private gift of 10 acres in what...
?
mi
from
Seattle, WA
Click here to add this to my saved trials